Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2020-06-19 Declaration of Voting R…
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 19, 2020, by Leap Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at the 2020 Annual Meeting of Stockholders held on June 16, 2020. It includes detailed voting results for director elections and ratification of the independent auditor. The document is short (3866 characters) and focuses on reporting the official voting results from the annual meeting. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not an Annual Report or Management Report, nor is it a Proxy Solicitation or Presentation. Therefore, the correct classification is DVA with high confidence.
2020-06-19 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock and pre-funded warrants by Leap Therapeutics, Inc. It includes detailed offering terms, underwriting information, risk factors, and legal disclaimers. The document is not a financial report, earnings release, or management discussion, but rather a disclosure document related to capital raising. It is a formal offering document used to inform investors about the securities being offered and the terms of the offering. This type of document fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2020-06-19 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 18, 2020, by Leap Therapeutics, Inc. It reports the entry into a material definitive agreement related to an underwritten public offering of common stock and pre-funded warrants. The document details the underwriting agreement, terms of the offering, use of proceeds, and related exhibits including the underwriting agreement, warrant form, legal opinion, and a press release. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising event and related agreements, which fits the category of Capital/Financing Update. The document length (9397 characters) and detailed description of the offering support this classification rather than a brief announcement or a regulatory filing fallback. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-06-18 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Leap Therapeutics, Inc. It includes detailed information about the offering of common stock and pre-funded warrants, underwriting details, risk factors, and other disclosures typical of a prospectus supplement. The document is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a regulatory filing unrelated to securities offerings. It is a capital markets document specifically related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual prospectus supplement, not merely an announcement of a report.
2020-06-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content includes termination of a material definitive agreement and announcement of a proposed public offering. It does not contain full financial statements or detailed financial analysis, but rather disclosures of specific corporate events. The document length is about 4,810 characters, which is typical for an 8-K filing. Therefore, this is a Regulatory Filing (RNS) as it does not fit into other specific categories like Annual Report, Earnings Release, or Capital/Financing Update directly, but is a general regulatory announcement.
2020-06-17 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about an orphan drug designation, which is filed as an exhibit. The document is short (3756 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-06-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.